IP Library Granted Patent US 9,644,179
Granted Patent B2
US 9,644,179 · App. 14/359,764 · Granted May 9, 2017

Use of PDL1 expressing cells to convert T cells into regulatory T cells

Inventors: James L. Riley (Downingtown, PA); Daniel H. Fowler (Bethesda, MD); Shoba Amarnath (Washington, DC)
Assignees: The Trustees of the University of Pennsylvania; The United States of America, as Represented By The Secretary, Department of Health And Human Services
C12N5/0637C12N2501/998C12N2502/99C12N2506/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,644,179
App. No.
14/359,764
Granted
May 9, 2017
Kind
B2
Abstract

The present invention provides methods and compositions for converting a T cell into a cell that exhibits at least one regulatory T cell phenotype. The converted T cell is generated by contacting a T cell with a cell that is modified to comprise an agent capable of activating PD1 signaling in a T cell. The converted T cell is useful for preventing, suppressing, blocking or inhibiting an immune response. For example the converted T cell is useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft versus host disease. The converted T cell can also be used to treat autoimmune diseases.

Claims (6)

1. A method of converting a pathogenic T cell into a cell that exhibits a regulatory T cell phenotype, the method comprising contacting the pathogenic T cell with a K562 cell modified to express an agent selected from the group consisting of PDL1, PDL2, and an anti-PD1 antibody, thereby converting said pathogenic T cell into a cell that exhibits a regulatory T cell phenotype.

2. The method of claim 1 , wherein said pathogenic T cell is a non-regulatory T cell selected from the group consisting of a CD4 + cell, a CD4 + CD25 − cell, and a CD4 + CD25 − 45RA + cell.

3. The method of claim 1 , wherein said pathogenic T cell is selected from the group consisting of a Th1 cell, a Th2 cell, a Th17 cell, and any combination thereof.

4. The method of claim 1 , wherein said converted regulatory T cell exhibits a phenotype selected from the group consisting of expression of Foxp3, suppression of effector T cell activation, and a combination thereof.

5. The method of claim 1 , wherein said modified K562 cell is irradiated.

6. The method of claim 1 , wherein said pathogenic T cell induces graft vs host disease (GVHD).

Assignments (3)
CONFIRMATORY LICENSE Recorded Oct 16, 2014
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034012/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2014
From: FOWLER, DANIEL H.; AMARNATH, SHOBA
To: GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 033526/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2014
From: RILEY, JAMES L.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 033399/0555 →
Continuity (3)
Provisional Application 61563273 · Nov 23, 2011
Provisional Application 61564174 · Nov 28, 2011
Related Publication 20140341933A1 · Nov 20, 2014